Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 35
- Registration Number
- NCT00336856
- Locations
- 🇺🇸
UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 100
- Registration Number
- NCT00330746
- Locations
- 🇮🇹
Ospedale di Prato, Prato, PO, Italy
🇮🇹Policlinico Giaccone, Palermo, PA, Italy
🇮🇹Ospedale S. Giuseppe, Milano, MI, Italy
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 31
- Registration Number
- NCT00327093
- Locations
- 🇫🇷
Jean-Alain Chayvialle, Lyon, France
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00326495
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00321100
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 10
- Registration Number
- NCT00319839
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer
- Conditions
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2010-09-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00315185
- Locations
- 🇺🇸
Consultants in Medical Oncology & Hematology Inc., Drexel Hill, Pennsylvania, United States
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 46
- Registration Number
- NCT00311857
- Locations
- 🇩🇪
University of Heidelberg, Heidelberg, Baden-Württemberg, Germany
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2020-02-19
- Target Recruit Count
- 60
- Registration Number
- NCT00305760
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Preoperative Chemoradiation With Capecitabine and Cetuximab
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 31
- Registration Number
- NCT00297128
- Locations
- 🇦🇹
Medical University of Graz, Oncology, Graz, Styria, Austria
🇦🇹Hospital Wiener Neustadt, Surgery, Wiener Neustadt, Lower Austria, Austria
🇦🇹Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.